Your browser is no longer supported. Please, upgrade your browser.
MTP Midatech Pharma Plc daily Stock Chart
Midatech Pharma Plc
Index- P/E- EPS (ttm)-1.34 Insider Own91.16% Shs Outstand48.72M Perf Week7.69%
Market Cap36.72M Forward P/E- EPS next Y- Insider Trans- Shs Float26.95M Perf Month0.51%
Income- PEG- EPS next Q- Inst Own- Short Float0.12% Perf Quarter-25.37%
Sales10.70M P/S3.43 EPS this Y- Inst Trans- Short Ratio0.20 Perf Half Y-45.77%
Book/sh2.11 P/B0.36 EPS next Y- ROA- Target Price- Perf Year-72.41%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.66 - 3.27 Perf YTD-9.99%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-76.95% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low14.00% ATR0.11
Employees85 Current Ratio- Sales Q/Q4.60% Oper. Margin- RSI (14)47.05 Volatility18.67% 16.76%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.58 Prev Close0.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume164.47K Price0.75
Recom- SMA20-5.06% SMA50-8.71% SMA200-42.72% Volume95,183 Change0.49%
May-25-18 07:00AM  Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer GlobeNewswire
May-03-18 08:20AM  Todays Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics ACCESSWIRE -14.19%
Apr-27-18 09:45AM  MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201 Zacks Small Cap Research
Mar-23-18 03:32AM  Where Münchener Tierpark Hellabrunn AGs (MUN:MTP) Earnings Growth Stands Against Its Industry Simply Wall St.
Mar-15-18 08:01AM  Midatech announces changes in Senior Management Team GlobeNewswire +28.55%
Mar-07-18 10:15AM  MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017 Zacks Small Cap Research
Feb-28-18 07:00AM  Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency GlobeNewswire
Feb-14-18 07:00AM  Midatech Pharma Plc: Trading update GlobeNewswire
Jan-16-18 07:01AM  Midatech and UCSF receive IND approval for DIPG treatment MTX110 GlobeNewswire
Jan-12-18 12:00PM  MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial Zacks Small Cap Research
Nov-27-17 03:00PM  Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas Zacks Small Cap Research -5.88%
Oct-27-17 01:59PM  Is Midatech Pharma Plc (AIM:MTPH) Undervalued? Simply Wall St. -6.08%
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.